GlassScriptPhysician profile
Lori R Mallory
NPI 1407288863
$4,137.11
in general payments reported to CMS, 2019-2025
34 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $248 · 2022: $481 · 2023: $1,752 · 2024: $1,493 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,408.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,262.50 | 2021-2024 | |
| Boston Scientific Corporation | $324.53 | 2022-2024 | |
| Averitas Pharma INC. | $261.88 | 2023-2024 | Qutenza |
| Pfizer INC. | $257.08 | 2023-2024 | |
| Lundbeck LLC | $250.93 | 2022-2024 | Vyepti |
| Saluda Medical Americas, INC. | $241.24 | 2024-2025 | Evoke |
| Scilex Pharmaceuticals INC. | $209.53 | 2022-2024 | Ztlido |
| Collegium Pharmaceutical, INC. | $193.28 | 2022-2024 | Belbuca, Xtampza |
| Nalu Medical, INC. | $147.87 | 2024 | Nalu Neurostimulation System |
| Lilly USA, LLC | $118.76 | 2022-2024 | Emgality |
| Biohaven Pharmaceutical Holding Company LTD. | $102.24 | 2022 | |
| Grt US Holding, INC. | $97.42 | 2022 | |
| Medtronic, INC. | $89.86 | 2023-2024 | Intellis Adaptivestim, Synchromedii |
| Spr Therapeutics, INC | $84.86 | 2022-2024 | Sprint Pns System |
| Mayne Pharma Commercial LLC | $65.70 | 2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.09 | 2024 | Relistor |
| Vertex Pharmaceuticals Incorporated | $42.68 | 2024 | |
| Painteq LLC | $39.40 | 2023-2024 | Painteq |
| Si-Bone, INC. | $39.36 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $32.30 | 2024 | Ajovy |
| Kowa Pharmaceuticals America, INC. | $27.56 | 2022-2023 | Seglentis |
| Pacira Pharmaceuticals Incorporated | $20.22 | 2023 | Zilretta, Iovera, Exparel |
| Bioventus LLC | $19.82 | 2024 | Gelsyn-3 |
| Supernus Pharmaceuticals, INC. | $18.67 | 2022 | |
| Ibsa Pharma INC. | $18.40 | 2023 | Tirosint, Licart |
| Impel Pharmaceuticals INC. | $16.49 | 2023 | Trudhesa |
| Relievant Medsystems, INC. | $16.19 | 2023 | Intracept |
| Fidia Pharma USA INC. | $15.47 | 2024 | Hymovis |
| Convatec INC. | $14.01 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.52 | 2021 | |
| Forte Bio-Pharma LLC | $13.50 | 2022 | |
| Abbott Laboratories | $13.17 | 2024 | Eterna |
| Glaxosmithkline, LLC. | $11.99 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Mallory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.